mRNA：治療學與全球市場

預計全球 mRNA 治療市場將保持平穩或略有下降，從 2025 年的 77.1 億美元下降至 2030 年底的 76.9 億美元，2025 年至 2030 年的複合年成長率為 -0.04%。

預計全球 COVID mRNA 治療市場規模將從 2025 年的 76.5 億美元小幅下降至 2030 年底的 75.8 億美元，在 2025 年至 2030 年的預測期內複合年成長率為 -0.2%。

全球非 COVID 疾病 mRNA 治療市場預計將從 2025 年的 6,170 萬美元成長到 2030 年底的 1.189 億美元，預測期內（2025-2030 年）的複合年成長率為 14%。

調查範圍

本報告分析了全球mRNA療法市場，包括2024年基準年的全球銷售額（百萬美元）、2025年的預估數據以及到2030年的年複合成長率(CAGR)預測。報告檢驗了各種類型的mRNA及其治療應用。報告還重點介紹了mRNA專利和臨床試驗，並討論了預測期內將影響市場的趨勢。報告還介紹了主要企業及其策略聯盟和夥伴關係關係。全球市場細分為北美、歐洲、亞太地區和世界其他地區。

報告內容

• 19 個資料表和 71 個附加表
• 全球傳訊RNA（mRNA）治療市場概況與分析
• 全球市場趨勢分析，包括 2022 年至 2024 年的收益數據、2025 年的估計值以及 2030 年的複合年成長率預測
• 全球 mRNA 市場規模和收益預測估計，以及按疾病類型、適應症和地區進行的市場佔有率分析
• 有關市場動態、機會和阻礙因素、技術進步、法規和宏觀經濟變數影響的事實和數據
• 波特五力模型、全球供應鏈和PESTLE分析的見解
• 專利分析，包括主要授權和公佈的專利
• 概述產業永續性趨勢和 ESG 發展，重點在於主要企業實施的 ESG 實踐、ESG評級和消費者意識
• 產業結構分析，包括企業市場占有率和排名、策略聯盟、併購和創業融資前景
• 主要企業，包括 Moderna Inc.、輝瑞公司、BioNTech SE、默克公司和賽諾菲

目錄

第1章執行摘要

第2章 市場概況

• 技術背景
• RNA療法的演變
• DNA 與 RNA 療法
• RNA療法
• mRNA作為治療劑
• mRNA疫苗的監管核准
• 美國關稅對mRNA療法市場的影響
• 結論

第3章市場動態

• 概述
• 市場促進因素
• 大流行病和流行病呈上升趨勢
• 意識到接種疫苗的必要性
• 投資mRNA治療藥物研究
• 市場限制
• mRNA疫苗的局限性
• 生產和物流障礙
• 市場機遇
• 個人化癌症疫苗
• mRNA療法在治療各種疾病的潛力

第4章：監理現狀

• 監管情景
• 監理機構概覽
• mRNA疫苗指南和標準
• 臨床前和臨床評估
• 生產和上市後監測
• 持續監控與風險管理

5. 研發管線和臨床試驗分析

• 摘要
• mRNA疫苗

第6章市場區隔分析

• 細分市場
• 按疾病類型分類的市場
• 摘要
• COVID mRNA疫苗
• 非COVID-19 mRNA疫苗和療法
• 按適應症分類的市場
• 癌症
• 感染疾病
• 罕見疾病
• 其他
• 按地區細分
• 按地區分類的市場
• 摘要
• 北美洲
• 歐洲
• 亞太地區
• 其他地區

第7章 新興科技與發展

• mRNA治療的新興技術
• 奈米粒子
• 修飾的mRNA
• 自動mRNA合成試劑套件
• 生物平台
• 人工智慧
• mRNA 治療公司的 AI 開發

第8章專利分析

第9章 mRNA 治療產業的永續性：ESG 視角

第10章 競爭訊息

• 摘要
• mRNA治療市場主要企業（2024年）
• 戰略分析
• 合作與夥伴關係
• 監管部門核准
• 臨床試驗數據
• 資金和津貼

第11章 附錄

• 調查方法
• 簡稱
• 來源
• 公司簡介
• ARCTURUS THERAPEUTICS INC.
• ASTRAZENECA
• BIOCINA
• BIONTECH SE
• CUREVAC SE
• ETHRIS GMBH
• GENNOVA BIOPHARMACEUTICALS LTD.
• GSK PLC.
• IMMORNA (HANGZHOU) BIOTECHNOLOGY CO. LTD.
• MERCK & CO. INC.
• MODERNA INC.
• NUTCRACKER THERAPEUTICS INC.
• PFIZER INC.
• PROVIDENCE THERAPEUTICS
• SANOFI
• STRAND THERAPEUTICS INC.

The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a compound annual growth rate (CAGR) of -0.04% during the forecast period of 2025 to 2030.

The global market for COVID mRNA therapeutics was valued at $7.65 billion in 2025 and is forecast to slightly decline to $7.58 billion by the end of 2030, at a CAGR of -0.2% during the forecast period of 2025 to 2030.

The global market for non-COVID diseases mRNA therapeutics was valued at $61.7 million in 2025 and is forecast to reach $118.9 million by the end of 2030, at a CAGR of 14% during the forecast period of 2025 to 2030.

Report Scope

The report analyzes the global market for mRNA therapeutics. It includes global revenue ($ millions) for the base year of 2024, estimated data for 2025 and projected compound annual growth rates (CAGRs) through 2030. The report examines the different types of mRNA and their applications for therapeutic use. It also focuses on mRNA patents and clinical trials and examines the trends affecting the market during the forecast period. The report profiles the leading companies and their strategic alliances and partnerships. The report segments the global market into North America, Europe, Asia-Pacific (APAC) and the Rest of the World (RoW).

Report Includes

• 19 data tables and 71 additional tables
• An overview and analysis of the global markets for messenger RNA (mRNA)-based therapeutics
• Analyses of the global market trends, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the size and revenue prospects for the global mRNA market, along with a market share analysis by disease type, indication, and region
• Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
• Insights derived from Porter's Five Forces model, global supply chain and PESTLE analyses
• Patent analysis, featuring key granted and published patents
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Moderna Inc., Pfizer Inc., BioNTech SE, Merck & Co., and Sanofi

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Growth Factors
• Emerging Technologies
• COVID mRNA Vaccines
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Technology Background
• Evolution of RNA Therapeutics
• DNA Therapeutics vs. RNA Therapeutics
• RNA Therapeutics
• mRNA as Therapeutics
• Regulatory Agency-Approved mRNA Vaccines
• Porter's Five Forces Analysis
• Potential for New Entrants
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitute Products or Services
• Industry Competition
• Impact of U.S. Tariffs on the mRNA Therapeutics Market
• Conclusion

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Rising Numbers of Pandemics and Epidemics
• Awareness of the Need for Vaccinations
• Investments in mRNA Therapeutics Research
• Market Restraints
• Limitations of mRNA Vaccines
• Production and Logistical Hurdles
• Market Opportunities
• Personalized Cancer Vaccines
• Potential of mRNA Drugs to Treat Various Diseases

Chapter 4 Regulatory Landscape

• Regulatory Scenario
• Overview of Regulatory Bodies
• Guidelines and Standards for mRNA Vaccines
• Preclinical and Clinical Evaluation
• Manufacturing and Post-Marketing Surveillance
• Continual Monitoring and Risk Management

Chapter 5 Pipeline and Clinical Trial Analysis

• Takeaways
• mRNA Vaccines

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by Disease Type
• Takeaways
• COVID mRNA Vaccines
• Non-COVID mRNA Vaccines and Therapeutics
• Market Breakdown by Indication
• Cancer
• Infectious Diseases
• Rare Diseases
• Others
• Geographic Breakdown
• Market Breakdown, by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Emerging Technologies and Developments

• Emerging Technologies in mRNA Therapeutics
• Nanoparticles
• Modified mRNA
• Automated mRNA Synthesis Kits
• Bio Platforms
• Artificial Intelligence
• AI Developments at mRNA Therapeutics Companies

Chapter 8 Patent Analysis

• Takeaways
• mRNA Publications
• List of Patents

Chapter 9 Sustainability in the mRNA Therapeutics Industry: An ESG Perspective

• Sustainability in the mRNA Therapeutics Industry
• ESG Risk Ratings
• ESG Performance Analysis
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC Research

Chapter 10 Competitive Intelligence

• Takeaways
• Leading Companies in the mRNA Therapeutics Market, 2024
• Strategic Analysis
• Collaborations and Partnerships
• Regulatory Approvals
• Clinical Trials Data
• Funding and Grants

Chapter 11 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ARCTURUS THERAPEUTICS INC.
• ASTRAZENECA
• BIOCINA
• BIONTECH SE
• CUREVAC SE
• ETHRIS GMBH
• GENNOVA BIOPHARMACEUTICALS LTD.
• GSK PLC.
• IMMORNA (HANGZHOU) BIOTECHNOLOGY CO. LTD.
• MERCK & CO. INC.
• MODERNA INC.
• NUTCRACKER THERAPEUTICS INC.
• PFIZER INC.
• PROVIDENCE THERAPEUTICS
• SANOFI
• STRAND THERAPEUTICS INC.

List of Tables

• Summary Table : Global Market for mRNA Therapeutics, by Disease, Through 2030
• Table 1 : Evolution of RNA Therapeutics
• Table 2 : Approved mRNA Vaccines, 2025
• Table 3 : Pandemics of the 21st Century
• Table 4 : Status of Clinical Trials for mRNA-based Drugs, 2025
• Table 5 : Clinical Trials for mRNA Vaccines, 2025
• Table 6 : Global Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 7 : Properties of the BNT162b2 Vaccine
• Table 8 : Properties of the mRNA-1273 Vaccine
• Table 9 : Properties of the CVnCoV Vaccine
• Table 10 : Global Market for COVID mRNA Therapeutics, by Region, Through 2030
• Table 11 : Global Market for Non-COVID mRNA Vaccines and Therapeutics, by Region, Through 2030
• Table 12 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
• Table 13 : Global Market for mRNA Therapeutics, by Region, Through 2030
• Table 14 : North American Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 15 : European Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 16 : Asia-Pacific Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 17 : RoW Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 18 : Organizations with the Most Published mRNA Patents
• Table 19 : Patents for mRNA Therapeutics, 2025
• Table 20 : Patents Related to mRNA Vaccines for Infectious Diseases, 2025
• Table 21 : Patents Related to mRNA Vaccines for Cancer Treatment, 2025
• Table 22 : Patents Focused on mRNA Delivery and Modification
• Table 23 : Focus Areas in ESG Metrics
• Table 24 : ESG Rankings for Major mRNA Therapeutics Companies, 2025*
• Table 25 : ESG: Environmental Overview
• Table 26 : ESG: Social Factors Overview
• Table 27 : ESG: Governance Overview
• Table 28 : Collaborations and Partnerships in the mRNA Therapeutics Market, 2023-2025
• Table 29 : Regulatory Approvals in the mRNA Therapeutics Industry, 2023-2025
• Table 30 : Clinical Trial Data in the mRNA Therapeutics Market, 2022-2025
• Table 31 : Funding and Grants in the mRNA Therapeutics Market, 2023-2025
• Table 32 : Abbreviations Used in this Report
• Table 33 : Arcturus Therapeutics Inc.: Company Snapshot
• Table 34 : Arcturus Therapeutics Inc.: Financial Performance, FY 2023 and 2024
• Table 35 : Arcturus Therapeutics Inc.: Product Pipeline
• Table 36 : Arcturus Therapeutics Inc.: News/Key Developments, 2024-2025
• Table 37 : AstraZeneca: Company Snapshot
• Table 38 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 39 : AstraZeneca: Product Pipeline
• Table 40 : AstraZeneca: News/Key Developments, 2025
• Table 41 : BioCina: Company Snapshot
• Table 42 : BioCina: Product Portfolio
• Table 43 : BioCina: News/Key Developments, 2023-2025
• Table 44 : BioNTech SE: Company Snapshot
• Table 45 : BioNTech SE: Financial Performance, FY 2023 and 2024
• Table 46 : BioNTech SE: Product Pipeline
• Table 47 : BioNTech SE: News/Key Developments, 2023-2024
• Table 48 : CureVac SE: Company Snapshot
• Table 49 : CureVac SE: Financial Performance, FY 2023 and 2024
• Table 50 : CureVac SE: Product Pipeline
• Table 51 : CureVac SE: News/Key Developments, 2024-2025
• Table 52 : Ethris GmbH: Company Snapshot
• Table 53 : Ethris GmbH: Product Pipeline
• Table 54 : Ethris GmbH: News/Key Developments, 2023-2025
• Table 55 : Gennova Biopharmaceuticals Ltd.: Company Snapshot
• Table 56 : Gennova Biopharmaceuticals Ltd.: Product Portfolio
• Table 57 : Gennova Biopharmaceuticals Ltd.: News/Key Developments, 2023
• Table 58 : GSK PLC: Company Snapshot
• Table 59 : GSK PLC: Financial Performance, FY 2023 and 2024
• Table 60 : GSK PLC: Product Pipeline
• Table 61 : GSK PLC: News/Key Developments, 2024
• Table 62 : Immorna Biotechnology Co. Ltd.: Company Snapshot
• Table 63 : Immorna Biotechnology Co. Ltd.: Product Pipeline
• Table 64 : Immorna Biotechnology Co. Ltd: News/Key Developments, 2024-2025
• Table 65 : Merck & Co. Inc.: Company Snapshot
• Table 66 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 67 : Merck & Co. Inc.: Product Pipeline
• Table 68 : Merck & Co. Inc.: News/Key Developments, 2023
• Table 69 : Moderna Inc.: Company Snapshot
• Table 70 : Moderna Inc.: Financial Performance, FY 2023 and 2024
• Table 71 : Moderna Inc.: Product Pipeline
• Table 72 : Moderna Inc.: News/Key Developments, 2024-2025
• Table 73 : Nutcracker Therapeutics Inc.: Company Snapshot
• Table 74 : Nutcracker Therapeutics Inc.: Product Portfolio
• Table 75 : Nutcracker Therapeutics Inc.: News/Key Developments, 2024-2025
• Table 76 : Pfizer Inc.: Company Snapshot
• Table 77 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 78 : Pfizer Inc.: Product Portfolio
• Table 79 : Pfizer Inc.: News/Key Developments, 2024
• Table 80 : Providence Therapeutics: Company Snapshot
• Table 81 : Providence Therapeutics: Product Pipeline
• Table 82 : Providence Therapeutics: News/Key Developments, 2022-2024
• Table 83 : Sanofi: Company Snapshot
• Table 84 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 85 : Sanofi: Product Pipeline
• Table 86 : Sanofi: News/Key Developments, 2024-2025
• Table 87 : Strand Therapeutics Inc.: Company Snapshot
• Table 88 : Strand Therapeutics Inc.: Product Pipeline
• Table 89 : Strand Therapeutics Inc.: News/Key Developments, 2024-2025

List of Figures

• Summary Figure : Global Market Shares of mRNA Therapeutics, by Disease, 2024
• Figure 1 : Porter's Five Forces Analysis
• Figure 2 : Snapshot of Market Dynamics
• Figure 3 : Factors Responsible for the Rising Number of Pandemics
• Figure 4 : Clinical Trials for mRNA Vaccines, by Disease Indication, 2023-2025
• Figure 5 : mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023-2025
• Figure 6 : mRNA Vaccine Candidates in Clinical Trials, by Study Type, 2023-2025
• Figure 7 : mRNA Vaccine Candidates in Clinical Trials, by Funding Source, 2023-2025
• Figure 8 : Global Market Shares of mRNA Therapeutics, by Disease Type, 2024
• Figure 9 : Global Cancer-Related Deaths, by Cancer Type, 2000-2030
• Figure 10 : Global Market Shares of mRNA Therapeutics, by Region, 2024
• Figure 11 : Emerging Technologies in mRNA Therapeutics
• Figure 12 : Patents on mRNA Therapeutics, 2010-2022
• Figure 13 : Patent Shares on mRNA Therapeutics, by Patent Classification, 2010-2021
• Figure 14 : Published mRNA-based Patents, 2019-2022
• Figure 15 : How a Strong ESG Proposition Can Benefit Businesses
• Figure 16 : Moderna's mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
• Figure 17 : BioNTech's mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
• Figure 18 : Arcturus Therapeutics Inc: Revenue Shares, by Business Unit, FY 2024
• Figure 19 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
• Figure 20 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
• Figure 21 : BioNTech SE: Revenue Shares, by Region/Country, FY 2024
• Figure 22 : GSK PLC: Revenue Shares, by Business Unit, FY 2024
• Figure 23 : GSK PLC: Revenue Shares, by Region/Country, FY 2024
• Figure 24 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 25 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 26 : Moderna Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 27 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 28 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 29 : Sanofi: Revenue Shares, by Country/Region, FY 2024